OBJECTIVE
Human herpesvirus 6 (HHV-6) is associated with a variety of complications in immunocompromised patients, but no studies have systematically and comprehensively assessed the impact of HHV-6 reactivation, and its interaction with cytomegalovirus (CMV), in intensive care unit (ICU) patients.
DESIGN
We prospectively assessed HHV-6 and CMV viremia by twice-weekly plasma PCR in a longitudinal cohort study of 115 adult, immunocompetent ICU patients. The association of HHV-6 and CMV reactivation with death or continued hospitalization by day 30 (primary endpoint) was assessed by multivariable logistic regression analyses.
SETTING
This study was performed in trauma, medical, surgical, and cardiac ICU’s at two separate hospitals of a large tertiary care academic medical center.
PATIENTS
A total of 115 CMV seropositive, immunocompetent adults with critical illness were enrolled in this study.
INTERVENTIONS
None.
MEASUREMENTS AND MAIN RESULTS
HHV-6 viremia occurred in 23% of patients at a median of 10 days. HHV-6B was the species detected in eight samples available for testing. Most patients with HHV-6 reactivation also reactivated CMV (70%). Severity of illness was not associated with viral reactivation. Mechanical ventilation, burn ICU, major infection, HHV-6 reactivation, and CMV reactivation were associated with the primary endpoint in unadjusted analyses. In a multivariable model adjusting for mechanical ventilation and ICU type, only co-reactivation of HHV-6 and CMV was significantly associated with the primary endpoint (adjusted odds ratio, 7.5; 95% CI, 1.9-29.9; p=0.005) compared to patients with only HHV-6, only CMV, or no viral reactivation.
CONCLUSIONS
Co-reactivation of both HHV-6 and CMV in ICU patients is associated with worse outcome than reactivation of either virus alone. Future studies should define the underlying mechanism(s) and determine whether prevention or treatment of viral reactivation improves clinical outcome.